Non-small Cell Lung Cancer (NSCLC) Clinical Trial
Official title:
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
NCT number | NCT02662634 |
Other study ID # | AGS-003-024 |
Secondary ID | |
Status | Withdrawn |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | March 2016 |
Est. completion date | March 2018 |
Verified date | March 2016 |
Source | GU Research Network, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Feasibility and Safety study of autologous dendritic cell immunotherapy (AGS-003-LNG) in patients with resectable non-small cell lung cancer.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | March 2018 |
Est. primary completion date | March 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: 1. Age = 19 years. 2. Newly diagnosed non-small cell lung cancer indicated for routine lobectomy, mediastinoscopy, wedge resection, thoracotomy or Video-assisted thoracoscopic surgery (VATS) procedures with tumor collection. 3. Stage III (T1-3, N1-2, M0) of any histology. 4. Scheduled for routine lobectomy, mediastinoscopy, wedge resection, thoracotomy or VATS procedures. 5. Signed and dated informed consent document for study participation. After tumor collection, potential subjects must meet all the following criteria to be enrolled in study treatment: 1. Successful RNA isolation and amplification from tumor sample (as determined by Argos). 2. Karnofsky performance status (KPS) score of 80-100. 3. Life expectancy of six months or greater. 4. NSCLC of any histology. 5. Resolution of all acute toxic effects of prior radiotherapy or surgical procedures to Grade = 1 according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 6. Negative serum pregnancy test for female subjects with reproductive potential, and agreement of all male and female subjects of reproductive potential to use a reliable form of contraception during the study and for 12 weeks after the last dose of study drug. 7. Able to abstain from taking prohibited drugs, either prescription or non-prescription, during the treatment phase of the study. 8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. 9. Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment. Exclusion Criteria: 1. Active autoimmune disease or condition requiring chronic immunosuppressive therapy 2. Any clinically significant condition that prohibits the initiation of standard of care. 3. Malignancies within the prior three years, except for: - treated in situ carcinomas or non-melanoma skin cancer. - adequately treated early stage breast cancer. - superficial bladder cancer. - non-metastatic prostate cancer with a normal prostate-specific antigen (PSA) level. 4. History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or evidence of brain or leptomeningeal disease. 5. Clinically significant disorders or conditions including - cardiovascular system. - renal system. - hepatic organ system. - coagulation disorders. 6. Clinically significant infections, including human immunodeficiency virus (HIV), syphilis, and active hepatitis B or C. 7. Pregnant or breastfeeding. 8. Any serious medical condition or illness considered by the investigator to constitute an unwarranted high risk for investigational treatment. |
Country | Name | City | State |
---|---|---|---|
United States | Cancer Research Network of Nebraska / Oncology Associates | Omaha | Nebraska |
Lead Sponsor | Collaborator |
---|---|
GU Research Network, LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety - Adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) V4.03 | Safety of AGS-003-LNG for subjects who receive 1 or more doses of AGS-003-LNG in combination with standard platinum-doublet chemotherapy with or without radiation. Adverse events will be collected per CTCAE V4.03. | 2 Years | |
Primary | Immunogenicity - Generation of Cluster of Differentiation-8 (CD8)+ Cluster of Differentiation (CD28)+ memory T-cells | Generation of CD8+CD28+ memory T-cells against tumor associated antigens in subject receiving 5 or more doses of AGS-003-LNG. | After 5th dose of AGS-003-LNG. Within 6 months. | |
Secondary | Efficacy - Overall survival | While the study is not powered for efficacy Overall Survival (including median and one year survival) be analyzed as an exploratory endpoints. | 2 Years | |
Secondary | Efficacy - Progression-free survival as measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. | While the study is not powered for efficacy, Progression Free Survival will be analyzed as an exploratory endpoint. | 2 Years | |
Secondary | Efficacy - Objective response rate. The number of patients with a Complete Response or Partial Response. | While the study is not powered for efficacy Objective Response Rate will be analyzed as an exploratory endpoint. | 2 Years | |
Secondary | Feasibility - Number of patients with a success in the manufacture of AGS-003-LNG. | AGS-003-LNG manufacturing success rate for non small cell lung cancer tumor RNA isolation from surgical resection. | 1 Month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06040541 -
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT03667820 -
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
|
Phase 2 | |
Completed |
NCT02025114 -
Selumetinib in Combination With Gefitinib in NSCLC Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT01994057 -
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
|
||
Completed |
NCT01438307 -
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01193959 -
Pemetrexed in Advanced Non-small Cell Lung Cancer
|
||
Recruiting |
NCT01028729 -
A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)
|
Phase 4 | |
Completed |
NCT00770588 -
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
|
Phase 4 | |
Active, not recruiting |
NCT05462717 -
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
|
Phase 1 | |
Completed |
NCT01951157 -
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
|
Phase 2 | |
Recruiting |
NCT01964157 -
An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
|
Phase 2 | |
Active, not recruiting |
NCT04026412 -
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
|
Phase 3 | |
Recruiting |
NCT05585320 -
A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03260491 -
HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT05207423 -
A Chart Review Study of Adults With Advanced NSCLC
|
||
Terminated |
NCT02608528 -
Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
|
||
Completed |
NCT01463423 -
Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
|
N/A | |
Recruiting |
NCT02927340 -
A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
|
Phase 2 | |
Recruiting |
NCT02521051 -
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 |